Xenon Pharmaceuticals Inc. (XENE): Depreciation & Amortization
$2.54M
Year ended 2025-12-31
$2.40M
Trailing 12 months to 2026-06-30
+21.9%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.54M | -0.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $2.56M | +24.2% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $2.06M | +46.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $1.41M | n/c | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $906.0K | +40.7% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $644.0K | +50.1% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $429.0K | -26.8% | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | $586.0K | -9.7% | 2020-03-09, From 2018-01-01 |
| 2017-12-31 | $649.0K | -24.9% | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | $864.0K | -16.8% | 2018-03-07, From 2016-01-01 |
| 2015-12-31 | $1.04M | +40.7% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $738.0K | +4.7% | 2017-03-08, From 2014-01-01 |
| 2013-12-31 | $705.0K | -10.3% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $786.0K | n/a | 2015-03-12, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $2.54M | -0.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $438.9K | -39.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $1.29M | -27.5% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $273.0K | -55.5% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $79.0K | -59.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $2.47M | +57.4% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $3.35M | -76.2% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $219.0K | +6.3% |
Compare XENE, ADAG, BOLT, OVID side by side · Screen every company in Pharmaceutical Preparations ↗